Elite
Pharmaceuticals, a specialty pharmaceutical company developing a pipeline of
abuse-deterrent opioids and niche generic products, today reported new
appointments to key management positions. Dr. Kennedy Smith, J.D., M.B.A. joins
Elite as Vice President of Legal; Dr. Jason LePree as Vice President of
Scientific Affairs; and Dr. Sophy Abraham as Vice President of Regulatory
Affairs.
“We are
pleased to welcome Ken, Jason, and Sophy to the Elite team and I’m thrilled
with the caliber of expertise that these individuals bring to Elite,” said
Nasrat Hakim, Elite’s President and Chief Executive Officer. “These additions
greatly strengthen our management team in key areas and enhance our internal
expertise in product development, regulatory compliance, and intellectual
property to support the development of our opioid abuse deterrent products.”
Prior to
his new role at Elite, Dr. Smith served as Chief Intellectual Property Counsel
for Alpharma Incorporated. Before that, he was Head of North American
Intellectual Property for Sanofi Aventis. In both roles, Dr. Smith held global
responsibilities for intellectual property pertaining to multiple business
units involved with many technologies. These included branded products, animal
health products, active pharmaceutical ingredients, generic drugs, and
vaccines. He also has a strong background in abuse deterrent intellectual
property. Dr. Smith holds a Ph.D. in Biochemistry from University of Houston,
an M.B.A from Lehigh University, and a J.D. from the University of Houston.
For his
new role at Elite, Dr. LePree brings a wealth of experience in formulations,
analytical research, and development. His previous position was Principal
Scientist, Formulations Research and Development for Capsugel. Dr. LePree also
draws upon a background in research and development, as he served in R&D
positions at Abon Pharmaceuticals, Penwest Pharmaceuticals, Novartis, and
Hoffman-LaRoche. With a B.S. in Pharmacy from Rutgers University and a Ph.D. in
Pharmacy from the University of Wisconsin, he is also active in academia as an
Adjunct Professor of Pharmacy at Long Island University.
Having
worked over 20 years at Teva Pharmaceuticals, Dr. Abraham has significant
regulatory and analytical experience. Prior to Elite, she served as Senior
Regulatory Associate at Teva. Dr. Abraham holds a B.S. in Zoology, Botany, and
Chemistry from the University of Kerala, India and a Ph.D. in Zoology from the
University of Baroda, India.
For more
information, visit www.elitepharma.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up
for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see
disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment